Acitretin Revisited

Acitretin over the last 20 years has proven useful in a number of dermatologic diseases. Evidence of efficacy, side-effect profile, and approach to its use will be reviewed.

Update on Drugs & Devices: November – December 2019

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa

Explore current and emerging therapies for Hidradenitis Suppurativa (HS), a chronic, painful skin condition. This article reviews the challenges of HS treatment and introduces novel approaches including biologics like secukinumab and innovative therapies in clinical trials.

Risankizumab in Adults with Psoriatic Arthritis

Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.

Update on Drugs and Drug News: September-October 2014

Update on Tedizolid phosphate tablets and IV injection (Sivextro™), Hyaluronic acidbased dermal filler (Restylane® Silk), Trifarotene, Icatibant SC injection (Firazyr®), C1 esterase inhibitor (Ruconest®), Methotrexate SC injection (Rasuvo™), Tavaborole 5% topical solution (Kerydin™), Nivolumab IV infusion (Opdivo®), Doxycycline hyclate tablets (Acticlate™)

A Review of Biologic Treatments for Psoriasis with Emphasis on Infliximab

Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

Update on Drugs and Drug News: January-February 2014

Update on Hyaluronic acid gel dermal filler (Juvéderm Voluma™XC), Methotrexate injection (Otrexup™), Luliconazole 1% cream (Luzu®), Smallpox vaccine (Imvamune®)

Update on Drugs and Drug News: November 2010

Update on drugs, approval dates, and comments. Drospirenone /ethinyl estradiol /levomefolate calcium + levomefolate calcium tablets (Beyaz™), Imiquimod 5% cream are covered.

Update on Drugs & Devices: March-April 2022

This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).

Update on Drugs and Drug News: May 2010

Update on drugs, approval dates, and comments. Imiquimod 3.75% cream (Zyclara™), Adapalene 0.1% lotion (Differin®), Polidocanol injection (Asclera®) are covered.

Off-label (unlabeled) Use of Drugs

Some of the most striking advances in dermatology have followed the off-label use of drugs. This review examines some of the issues surrounding off-label use of drugs by dermatologists, illustrates the need for such use and looks at possible changes in the regulatory system.

Update on Drugs and Drug News – May 2006

Update on Fluocinonide VANOS™ 0.1% Cream, Infliximab Remicade®, Tigecycline TYGACIL®, as well as drug warnings and industry news.

Efficacy of Acitretin in Severe Psoriasis

Acitretin (SORIATANE®, Roche Pharmaceuticals) is an aromatic retinoid, effective in the treatment of severe psoriasis. This study highlights data from two existing clinical trials to capture PASI 50 and PASI 75 responder rates which represent a common metric used in current psoriasis clinical trials.

Update on Drugs and Drug News – October 2007

Update on Nanocrystalline Silver Cream NPI32101, Daptomycin for Injection CUBICIN®, Oral Alitretinoin BAL4079, Smallpox Vaccine ACAM2000, and news about new US FDA regulations.

Finasteride for Male Pattern Hair Loss

Finasteride 1 mg (Propecia®, Merck) was approved by the US FDA December, 1997 for the treatment of male pattern hair loss (androgenetic alopecia, AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior mid-scalp area.

Many Common Drugs in Dermatology are Light, Temperature, or Moisture-Sensitive

In this article storage guidelines for common dermatology drugs are provided. We suspect that drug degradation is common due to improper storage and that improved patient instruction regarding storage will reduce degradation and alleviate some of the danger associated with improper storage and usage patterns.

Prevention of Polymorphous Light Eruption and Solar Urticaria

Polymorphous light eruption (PLE) and solar urticaria (SU) are two photodermatoses that are induced by ultraviolet radiation and sometimes by visible light. This article will review the various means of preventing PLE and SU with an emphasis on the role of sunscreens.

Update on Drugs and Drug News: February 2012

Update on drugs, approval dates, and comments. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Hyaluronic acid-based dermal filler (Belotero® Balance), Drospirenone 3 mg + ethinyl estradiol 0.02 mg (Vestura™) are covered.

Skin and Diet: An Update on the Role of Dietary Change as a Treatment Strategy for Skin Disease

An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. This article takes a high level overview of the role that diet may play in these conditions.

Novel Topical Drug Delivery Systems and Their Potential Use in Acne Vulgaris

A vast spectrum of topical anti-acne agents has emerged in response to new insights that have been gained through the understanding of disease pathophysiology and the need for clinicians to adopt an individualized therapeutic approach.

Topical Clascoterone for Acne Vulgaris

Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.

Alternative Treatments For Atopic Dermatitis: A Selected Review

Herbal remedies are largely unregulated, but often talked about among patients. Many may have scientific merit and clinical benefit, but they are still scientifically invalid and inadequately monitored. Dermatologists need information about herbal remedies to better serve their Atopic Dermatitis patients.

Chronic Urticaria: Following Practice Guidelines

Urticaria is a common, mast-cell-driven disease, characterized clinically by the development of wheals, angioedema, or both. A large body of data has demonstrated that omalizumab, a biologic agent, is safe and effective in the treatment of H1- antihistamine refractory urticaria and should be considered as a third-line agent, with cyclosporin A reserved for fourth-line therapy.

Systemic and Light Therapies for the Management of Childhood Psoriasis: Part II

The choice of treatment for psoriasis in children, as in adults, is determined by disease acuity, morphology, distribution, and severity. Part II of this 2-part series features an overview of systemic and light therapies including their varying degrees of effectiveness, potential side-effects and applications in clinical practice.

Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses

A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.

Update on Drugs and Drug News: May 2012

Update on drugs, approval dates, and comments. Belimumab Adapalene (0.3% gel Differin®), Vemurafenib tablet (Zelboraf®), Wound care spray (Granulox®), as well as devices like the laser device for onychomycosis Harmony® XL are covered.

New Antibiotics in the Management of Acute Bacterial Skin and Skin Structure Infections

This article reviews the mechanism of action, efficacy, bacterial coverage, and potential side effects for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone.

Topical Antipsoriatics

With growing public reluctance to use systemic medications we can expect topical treatments for psoriasis and other skin conditions to become increasingly important in the future. These drugs are useful not only to control this disease, but also to limit the irritation caused by medications such as tazarotene and anthralin.

Non-Invasive Gene Expression Testing to Rule Out Melanoma

The Pigmented Lesion Assay (PLA) is a gene expression test that helps rule out melanoma and has the potential to reduce the need for surgical biopsies of atypical pigmented skin lesions.

Transition of Topical Therapy Formulation in Psoriasis: Insights from a Canadian Practice Reflective

The benefits of transitioning from Cal/BD ointment or gel to aerosol foam formulation in this Canadian patient population were similar to those reported in clinical studies and were seen consistently among patients with a range of treatment priorities and with differing history of psoriasis severity and treatment history.

Update on Drugs and Drug News: November-December 2014

Update on Omalizumab (Xolair®), Pembrolizumab (Keytruda®), Oritavancin (Orbactiv™), and Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®)

Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy". Adverse effects of such treatments are thought to be less severe, but can still be significant.

Butenafine: An Update of Its Use in Superficial Mycoses

Butenafine may be effective and safe in the treatment of interdigital tinea pedis (apply twice daily for 1 week or once daily for 4 weeks), tinea corporis/ tinea cruris (apply twice daily for 2 weeks), and pityriasis versicolor (apply once daily for two weeks).

5-Fluorouracil 0.5% Cream for Multiple Actinic or Solar Keratoses of the Face and Anterior Scalp

Carac® (5-fluorouracil 0.5% cream, Aventis Pharma) was approved by the US FDA in October 2000, for the treatment of multiple actinic or solar keratoses involving the face and anterior scalp.

Update on Drugs and Drug News: October 2011

Update on drugs, approval dates, and comments. IncobotulinumtoxinA injection (Xeomin®), Vemurafenib tablets (Zelboraf™ cobas®), Icatibant injection (Firazyr®) are covered.

Update on Drugs and Drug News: May-June 2013

Update on Acyclovir 50 mg buccal tablets (Sitavig®), Acyclovir 5% + hydrocortisone 1% cream (Xerese®), Botulinum toxin type A for injection (Dysport®), Desoximetasone 0.25% topical spray (Topicort®), Carbinoxamine maleate extendedrelease oral suspension (Karbinal™ ER), and C1-esterase inhibitor (Berinert®)

Sarecycline: A Narrow-Spectrum Antibiotic

Sarecycline is a novel antibiotic that has shown significant promise in acne treatment due to its narrow-spectrum activity and weight-based dosing.

Use of Cutaneous Lasers and Light Sources: Appropriate Training and Delegation

In recent years, there has been increasing concern that laser, light, and cosmetic surgery are being used by poorly trained professionals, resulting in preventable injuries to patients. These guidelines delineate appropriate qualifications, and also describe the circumstances and settings in which delegation is appropriate.

The Use Of Low Dose Oral Contraceptives for the Management of Acne

There is compelling evidence that oral contraceptives (OCs) are effective in the management of mild-moderate acne vulgaris, as well as cumulative evidence that elevated levels of androgens in acne patients, relative to appropriate controls, are an underlying pathophysiological factor in acne.

Poly-L-Lactic Acid as a Facial Filler

Poly-L-lactic acid is a filler recently approved by the US FDA for the correction of facial lipoatrophy in patients infected with the human immunodeficiency virus (HIV). Currently, poly-L-lactic acid, sold under the brand name Sculptra™ (Dermik), is the only product approved by the FDA specifically for this indication.

POPULAR

Advertisement